Nanette Cocero

Nanette Cocero is the Director of HilleVax, a biopharmaceutical company focused on the development and commercialization of novel vaccines. Prior to HilleVax, Cocero was the Global President of Pfizer Vaccines, leading the development, commercialization, and delivery of innovative vaccines to drive the prevention of serious and life-threatening conditions. Cicero managed a $6B+ global business and a diverse vaccine portfolio aimed at protecting lives at all stages, from infants to older adults. Cicero is the former Chair of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) Vaccine CEO Steering Committee, advocating for policies and practices that foster vaccine innovation and driving collaboration across the biopharmaceutical industry. In this position and her role at Pfizer, she served as a key thought leader for the industry during the COVID-19 pandemic, helping to accelerate the development and production of a COVID-19 vaccine and advocating for equitable access to diagnostics, therapeutics, and vaccines around the world.

She also serves on the Leadership Council for the Milken Institute's Center for the Future of Aging. Prior to leading Vaccines, Cocero was the Regional President of Emerging Markets for Pfizer's Innovative Health business. Before joining Pfizer, she was a management consultant and a Research Fellow for the University of Pennsylvania, Department of Pharmacology. She earned a BSc in chemistry from Cornell University, a Ph.D. in pharmacology from the University of Pennsylvania, and an MBA from The Wharton Business School.